Molecular Compound ImmunoTherapeutics

Molecular Compound Inc. (MCI) is a clinical-stage biotechnology company developing a novel class of cancer treatments termed "Molecular Compound ImmunoTherapeutics." The company's proprietary platform focuses on designing small molecule inhibitors that mimic the therapeutic effects of monoclonal antibodies, specifically targeting immune checkpoints such as PD-L1 and CTLA-4. These small molecule alternatives are designed to offer superior tissue penetration, oral bioavailability, and lower production costs compared to traditional biologics. MCI's lead candidate, MCI-001, is a small molecule PD-L1 inhibitor currently being evaluated in clinical trials for the treatment of various solid tumors. By bridging the gap between small molecules and biologics, the company aims to provide more accessible and effective immunotherapy options for patients worldwide. The company operates out of headquarters in Seoul, South Korea, with additional research facilities in the United States.